Moleculin Biotech Inc (MBRX) - Net Assets
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has net assets worth $15.01 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.13 Million) and total liabilities ($7.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Moleculin Biotech Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.01 Million |
| % of Total Assets | 67.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | -81.0% |
| 10-Year Change | 0.31% |
| Growth Volatility | 122.92 |
Moleculin Biotech Inc - Net Assets Trend (2015–2025)
This chart illustrates how Moleculin Biotech Inc's net assets have evolved over time, based on quarterly financial data. See Moleculin Biotech Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Moleculin Biotech Inc (2015–2025)
The table below shows the annual net assets of Moleculin Biotech Inc from 2015 to 2025. For live valuation and market cap data, see MBRX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.01 Million | +150.98% |
| 2024-12-31 | $5.98 Million | -77.07% |
| 2023-12-31 | $26.07 Million | -50.04% |
| 2022-12-31 | $52.19 Million | -33.93% |
| 2021-12-31 | $78.99 Million | +341.57% |
| 2020-12-31 | $17.89 Million | +14.89% |
| 2019-12-31 | $15.57 Million | +9.10% |
| 2018-12-31 | $14.27 Million | -16.63% |
| 2017-12-31 | $17.12 Million | +14.42% |
| 2016-12-31 | $14.96 Million | +2108.91% |
| 2015-12-31 | $-744.70K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Moleculin Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20525564000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.02% |
| Other Comprehensive Income | $10.00K | 0.07% |
| Other Components | $221.00 Million | 1472.72% |
| Total Equity | $15.01 Million | 100.00% |
Moleculin Biotech Inc Competitors by Market Cap
The table below lists competitors of Moleculin Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prochem S.A.
WAR:PRM
|
$13.02 Million |
|
Trust Finance Indonesia Tbk
JK:TRUS
|
$13.03 Million |
|
Skin Elements Ltd
AU:SKN
|
$13.04 Million |
|
Guardforce AI Co Ltd
NASDAQ:GFAI
|
$13.04 Million |
|
Nuvotec
KQ:060260
|
$13.02 Million |
|
Huadi International Group Co Ltd
NASDAQ:HUDI
|
$13.01 Million |
|
Wegmans Holdings Berhad
KLSE:0197
|
$13.00 Million |
|
Mico BioMed Co. Ltd.
KQ:214610
|
$13.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Moleculin Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,979,000 to 15,006,000, a change of 9,027,000 (151.0%).
- Net loss of 33,560,000 reduced equity.
- Dividend payments of 104,000 reduced retained earnings.
- New share issuances of 25,765,000 increased equity.
- Other comprehensive income increased equity by 51,000.
- Other factors increased equity by 16,875,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.56 Million | -223.64% |
| Dividends Paid | $104.00K | -0.69% |
| Share Issuances | $25.77 Million | +171.7% |
| Other Comprehensive Income | $51.00K | +0.34% |
| Other Changes | $16.88 Million | +112.46% |
| Total Change | $- | 150.98% |
Book Value vs Market Value Analysis
This analysis compares Moleculin Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-294.35 | $2.80 | x |
| 2016-12-31 | $3424.99 | $2.80 | x |
| 2017-12-31 | $2074.15 | $2.80 | x |
| 2018-12-31 | $1239.64 | $2.80 | x |
| 2019-12-31 | $860.37 | $2.80 | x |
| 2020-12-31 | $681.36 | $2.80 | x |
| 2021-12-31 | $1102.19 | $2.80 | x |
| 2022-12-31 | $684.22 | $2.80 | x |
| 2023-12-31 | $329.94 | $2.80 | x |
| 2024-12-31 | $43.41 | $2.80 | x |
| 2025-12-31 | $1.27 | $2.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Moleculin Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -223.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.47x
- Recent ROE (-223.64%) is below the historical average (-102.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-673.89K |
| 2016 | -26.25% | 0.00% | 0.00x | 1.10x | $-5.42 Million |
| 2017 | -57.28% | -108944.44% | 0.00x | 1.14x | $-11.52 Million |
| 2018 | -83.21% | 0.00% | 0.00x | 1.37x | $-13.30 Million |
| 2019 | -84.81% | 0.00% | 0.00x | 1.62x | $-14.76 Million |
| 2020 | -97.01% | 0.00% | 0.00x | 1.63x | $-19.14 Million |
| 2021 | -20.12% | 0.00% | 0.00x | 1.06x | $-23.79 Million |
| 2022 | -55.61% | 0.00% | 0.00x | 1.10x | $-34.24 Million |
| 2023 | -114.18% | 0.00% | 0.00x | 1.47x | $-32.38 Million |
| 2024 | -363.99% | 0.00% | 0.00x | 2.83x | $-22.36 Million |
| 2025 | -223.64% | 0.00% | 0.00x | 1.47x | $-35.06 Million |
Industry Comparison
This section compares Moleculin Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Moleculin Biotech Inc (MBRX) | $15.01 Million | 0.00% | 0.47x | $13.02 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more